Viking Global Investors LP Gracell Biotechnologies Inc. Transaction History

Viking Global Investors LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$1.83 - $5.52 $899,714 - $2.71 Million	-491,647 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$5.65 - $14.9 $4.89 Million - $12.9 Million	-866,212 Reduced 63.79%	491,647 $2.97 Million
Q3 2021 Nov 15, 2021	BUY	$9.91 - $14.84 $272,832 - $408,560	27,531 Added 2.07%	1,357,859 $18.8 Million
Q2 2021 Aug 16, 2021	SELL	$9.75 - $18.42 $143,793 - $271,658	-14,748 Reduced 1.1%	1,330,328 $17.3 Million
Q1 2021 May 17, 2021	BUY	$14.7 - $30.57 $19.8 Million - $41.1 Million	1,345,076 New	1,345,076 $20.7 Million

75.1K

Ticker GRCL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,674,096
Description
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the tre...

Get notified when there are updates to the investment portfolio of Viking Global Investors LP, based on Form 13F filings with the SEC.

Stay updated on Viking Global Investors LP with notifications on news.